StemCells Inc (STEM.O)
29 Sep 2016
* Respective boards of directors of stemcells and microbot have approved merger agreement - sec filing
StemCells Inc said it would wind down operations after the company terminated a mid-stage trial testing its therapy in spinal cord injury, sending its shares plummeting 85 percent.
* Shares plunge 85 pct (Adds analyst comment, details; updates shares)
May 31 StemCells Inc said on Tuesday it had terminated a mid-stage trial in spinal cord injury and that its board had decided to wind down the company.
* Files for rights offering for up to $30 million - SEC filing Source text for Eikon: Further company coverage:
* Trading common stock on Nasdaq Capital Market will continue, on a split-adjusted basis, on may 9, 2016 Further company coverage: (Bengaluru Newsroom; +1 646 223 8780; )
* Trading of common stock on Nasdaq capital market will continue, on a split-adjusted basis, on May 9, 2016 Source text for Eikon: Further company coverage:
* Stemcells inc says presents interim results from its phase ii pathway study in chronic cervical spinal cord injury
|Novartis AG (NOVN.S)||CHF75.85||-1.40|
|Pfizer Inc. (PFE.N)||$33.32||-0.67|
|Roche Holding Ltd. (ROG.S)||CHF238.50||-3.30|
|Roche Holding Ltd. (RO.S)||CHF239.70||-3.20|
|Merck & Co., Inc. (MRK.N)||$61.91||-1.39|
|Sanofi SA (SASY.PA)||€67.23||-0.80|
|Abbott Laboratories (ABT.N)||$41.44||-0.85|
|Amgen, Inc. (AMGN.OQ)||$165.45||--|
|Merck KGaA (MRCG.DE)||€94.31||-1.57|
|Biogen Inc (BIIB.OQ)||$305.78||--|
Earnings vs. Estimates
Analyst Research Reports
Provider : New Constructs, LLC
Provider : Thomson Reuters Stock Report
Provider : S&P Capital IQ Quantitative Report
Provider : Pechala's Reports
StemCells Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider : Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.